StreetInsider.com News Articles

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Longeveron adds Dr. Deborah Ascheim to its board of directors

Thu, 23 Jul 2026 09:15:17 -0400

Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026.

Prior to her current roles, Dr. Ascheim served

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Thu, 23 Jul 2026 09:15:00 -0400

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications.